Real-world efficacy and safety of pyrotinib in patients with HER2-positive metastatic breast cancer: A prospective real-world study

被引:6
作者
Zhang, Qiongwen [1 ,2 ]
He, Ping [3 ]
Tian, Tinglun [3 ]
Yan, Xi [3 ]
Huang, Juan [4 ]
Zhang, Zhang [5 ]
Zheng, Hong [3 ,6 ]
Zhong, Xiaorong [3 ,6 ]
Luo, Ting [3 ,6 ]
机构
[1] Sichuan Univ, Canc Ctr, West China Hosp, Dept Radiat Oncol,Dept Head & Neck Oncol, Chengdu, Peoples R China
[2] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu, Peoples R China
[3] Sichuan Univ, West China Hosp, Breast Dis Ctr, Canc Ctr, Chengdu, Peoples R China
[4] Sichuan Univ, West China Hosp, Dept Radiol, Chengdu, Peoples R China
[5] Sichuan Univ, West China Hosp, Dept Pathol, Chengdu, Peoples R China
[6] Sichuan Univ, West China Hosp, Innovat Ctr Biotherapy, Multi Lab Breast Dis,State Key Lab Biotherapy,Natl, Chengdu, Peoples R China
关键词
HER2-positive breast cancer; real-world studies; brain metastase; pyrotinib; tyrosine kinase inhibitors; TYROSINE KINASE INHIBITOR; BRAIN METASTASES; CHEMOTHERAPY; TRASTUZUMAB; CISPLATIN;
D O I
10.3389/fphar.2023.1100556
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Pyrotinib, a novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor, shows encouraging anticancer activity and acceptable tolerability in multiple phase II and phase III randomized clinical trials, but the real-world data of pyrotinib, especially the outcomes in HER2-positive metastatic breast cancer, have been rarely reported. Here, we evaluated the treatment outcomes of pyrotinib in real-world practice in patients with HER2-positive metastatic breast cancer (MBC).Methods: This was a prospective, real-world, observational cohort study. Through the Breast Cancer Information Management System, HER-2 positive MBC patients treated with pyrotinib between 2017/06 and 2020/09 were included. Provider-reported objective response rate, progression-free survival (PFS), and overall survival (OS) were considered in the assessment of treatment outcomes. Tumor responses to pyrotinib treatment were calculated using RECIST 1.1. Adverse events were evaluated using clinical records.Results: The trial involved 113 individuals who were receiving pyrotinib treatment, with an average age of 51 years. Complete response, partial response and stable disease were observed in 9 (8.0%), 66 (58.4%), and 17 (15.0%) patients, respectively, while progressive disease was recorded in 20 (17.7%) patients. After a median follow-up of 17.2 months, the median PFS was 14.1. The most common adverse events of any grade were diarrhea (87.6%), vomiting (31.9%), and palmar-plantar erythrodysesthesia (26.6%). Among the patients with brain metastases, the median PFS and OS were 15.2 and 19.8 months, respectively. In addition, pyrotinib has similar efficacy in various subtypes of HER2-positive MBC patients, as shown by the lack of a significant difference of PFS and OS among pyrotinib-treated patients with or without brain metastases, or patients using pyrotinib as first-line, second-line, third-line or beyond therapies.Conclusion: Our real-world results demonstrated equivalent clinical efficacy in HER-2 positive MBC patients compared to phase II and phase III clinical trials with pyrotinib, and promising outcomes in patients with brain metastases.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] An exploration of the optimal combination chemotherapy regimen based on neoadjuvant therapy containing pyrotinib for HER2-positive breast cancer: A multicenter real-world study
    Wang, Shan
    Jin, Zining
    Li, Zhaohui
    Zhu, Guolian
    Liu, Bin
    Zhang, Dianlong
    Tang, Shuhong
    Yao, Fan
    Wen, Jian
    Zhao, Yi
    Wang, Xiaolan
    Jin, Feng
    Wang, Jia
    TRANSLATIONAL ONCOLOGY, 2025, 51
  • [32] Real-world data of pyrotinib-based therapy for patients with brain metastases of HER2-positive advanced breast cancer: a single-center retrospective analysis and molecular portraits
    Wang, Hui
    Liu, Qiaoyan
    Zhang, Mi
    Zhang, Juan
    Ran, Ran
    Ma, Yingying
    Yang, Jiao
    Wang, Fan
    He, Shujuan
    Zhao, Xiaoai
    Wang, Le
    Zhang, Lingxiao
    Dong, Danfeng
    Yang, Jin
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [33] Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab
    Debien, Veronique
    Marta, Guilherme Nader
    Agostinetto, Elisa
    Sirico, Marianna
    Jacobs, Flavia
    Molinelli, Chiara
    Moreau, Michel
    Paesmans, Marianne
    De Giorgi, Ugo
    Santoro, Armando
    Taylor, Donatienne
    Duhoux, Francois P.
    Botticelli, Andrea
    Barchiesi, Giacomo
    Speranza, Iolanda
    Lambertini, Matteo
    Wildiers, Hans
    de Azambuja, Evandro
    Piccart, Martine
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2023, 190
  • [34] Real-World Evidence: A Comparison of the Australian Herceptin Program and Clinical Trials of Trastuzumab for HER2-Positive Metastatic Breast Cancer
    Bonny Parkinson
    Rosalie Viney
    Marion Haas
    Stephen Goodall
    Preeyaporn Srasuebkul
    Sallie-Anne Pearson
    PharmacoEconomics, 2016, 34 : 1039 - 1050
  • [35] Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program
    Le Du, Fanny
    Carton, Matthieu
    Bachelot, Thomas
    Saghatchian, Mahasti
    Pistilli, Barbara
    Brain, Etienne
    Loirat, Delphine
    Vanlemmens, Laurence
    Vermeulin, Thomas
    Emile, George
    Goncalves, Anthony
    Ung, Mony
    Robert, Marie
    Jaffre, Anne
    Desmoulins, Isabelle
    Jouannaud, Christelle
    Uwer, Lionel
    Ferrero, Jean Marc
    Mouret-Reynier, Marie-Ange
    Jacot, William
    Chevrot, Michael
    Delaloge, Suzette
    Dieras, Veronique
    ONCOLOGIST, 2023, 28 (10) : e867 - e876
  • [36] Efficacy and safety of disitamab vedotin after trastuzumab for HER2 positive breast cancer: a real-world data of retrospective study
    Li, Chao
    Sun, Luhao
    Liu, Zhaoyun
    Sun, Haiyin
    Wang, Xinzhao
    Yu, Qian
    Yu, Zhiyong
    AMERICAN JOURNAL OF CANCER RESEARCH, 2024, 14 (02): : 869 - 879
  • [37] Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9)
    Torrisi, Rosalba
    Palumbo, Raffaella
    De Sanctis, Rita
    Vici, Patrizia
    Bianchi, Giulia Valeria
    Cortesi, Laura
    Leonardi, Vita
    Gueli, Rossana
    Fabi, Alessandra
    Valerio, Maria Rosaria
    Gambaro, Anna Rita
    Tagliaferri, Barbara
    Pizzuti, Laura
    Cazzaniga, Marina Elena
    Santoro, Armando
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 190 (01) : 103 - 109
  • [38] Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center
    Piezzo, Michela
    D'Aniello, Roberta
    Avallone, Ilaria
    Barba, Bruno
    Cianniello, Daniela
    Cocco, Stefania
    D'Avino, Antonio
    Di Gioia, Germira
    Di Lauro, Vincenzo
    Fusco, Giuseppina
    Piscitelli, Raffaele
    von Arx, Claudia
    De Laurentiis, Michelino
    Maiolino, Piera
    PHARMACEUTICS, 2021, 13 (05)
  • [39] Real-world impact of anti-HER2 therapy-related cardiotoxicity in patients with advanced HER2-positive breast cancer
    Conduit, C.
    de Boer, R. H.
    Lok, S.
    Gibbs, P.
    Malik, L.
    Loh, Z.
    Yeo, B.
    Greenberg, S.
    Devitt, B.
    Lombard, J.
    Nottage, M.
    Collins, I.
    Torres, J.
    Nolan, M.
    Nott, L.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 (06) : 356 - 362
  • [40] Real-world patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancer
    Kaufman, Peter A.
    Neuberger, Edward
    Schwartz, Naomi R. M.
    Wang, Shu
    Liu, Yutong
    Hsu, Ling-, I
    Bartley, Karen
    Blahna, Matthew T.
    Pittner, Brian T.
    Wong, Gabriel
    Anders, Carey
    FRONTIERS IN ONCOLOGY, 2023, 13